International Lung Cancer Summit (ILCS) 2026

One day across NSCLC and SCLC, chaired by Solange Peters and Alfredo Addeo: ctDNA, EGFR and ALK, other actionable drivers, KRAS, the ADC wave, early-stage immunotherapy, T-cell engagers in SCLC, and a first-line ES-SCLC debate. Reconstructed from the published programme, with 53 slides from 28 curated posts pinned to the talk they came from. Captions are verbatim.

Programme Items

Talks with Posts

Slides Captured

Faculty

Trials Linked

The Programme, Talk by Talk

The full scientific programme as published by the organizer. Under each talk are the curated posts that document it, with the slides, the slide text, and a link back to the original post.

Morning Programme

Chairs · Solange Peters & Alfredo Addeo

09:45–12:30 CET5 of 6 with posts

09:45 Welcome & introductionSolange Peters · Alfredo Addeo

09:50 ctDNA-guided decisions in lung cancer: ready or not?Millie Das

🆙 #ILCS2026 @LungSummit 🔥ctDNA-Guided Decisions in Lung Cancer: Ready or Not? 🎙️ @DasMillie11 ▶️Registration is open: #LCSM @OncoAlert

ILCS 2026 slide — Millie Das, ctDNA-guided decisions in lung cancer: ready or not?: UNDERSTANDING THE ASSAYS

[Slide 1] UNDERSTANDING THE ASSAYS TUMOR-INFORMED VS TUMOR-NAÏVE ASSAYS Tumor-informed | Tumor-naïve Requires tissue biopsy | No need for biopsy Personalized assay | Off the shelf assay Longer turnaround time | Shorter turnaround time Does not account for tumor heterogeneity | Can detect clonal variants that emerge during follow-up Potential for better sensitivity and specificity | Limited sensitivity and specificity LOD: ~1–100 ppm (MRD Detection) | LOD: 200–5,000 ppm (Tumor Profiling/ Treatment Monitoring) Adapted from Pellini B, Chaudhuri AA. J Clin Oncol 2022;40:567–75; Northcott J, et al. Oncotarget 2024;15:200–18; Zhao J, et al. Mol Diagn Ther 2023;27:753–68 ILCS 2026 [photo of speaker inset at right] --- [Slide 2] ctDNA AS A PROGNOSTIC MARKER Foresight CLARITY: PhasED-Seq Foresight Diagnostics (now Natera); tumor-informed A | SNV-based MRD [Kaplan–Meier curve] Freedom from recurrence (%); Months from surgery HR=3.07 [1.1 - 8.6] p=0.026 ctDNA- (n=39) ctDNA+ (n=6) LOD = 84 ppm B | PhasED-Seq MRD [Kaplan–Meier curve] Freedom from recurrence (%); Months from surgery HR=11.38 [4.1 - 31.5] p=1e-08 ctDNA- (n=33) ctDNA+ (n=12) LOD = 1 ppm Involves WES/deep targeted NGS of tumor with matched normal sample (somatic vs germline) Identifies clusters of co-occurring somatic mutations (≥2 phased variants) that exist on same DNA fragment Patient-specific assay designed to track multiple phased variants in plasma LOD= 1 ppm Achieves ultra-low error rates→ improved specificity compared to single-variant detection Clinical sensitivity 67% (12/18) with PhasED-Seq vs 28% (5/18) with SNV-based CAPP-Seq Requires multiple somatic mutations to be observed together on the same fragment→ reduces background error and false positives [source, left edge cut off] ...rom Isbell JM, et al. ASCO 2024, abstract 8078 ILCS 2026 [photo of speaker inset at right] --- [Slide 3] PREDICTIVE ROLE OF ctDNA GOAL OF MRD ASSAYS IN EARLY-STAGE NSCLC Therapeutic decision making MRD assay Baseline (pre-surgery) | Surgery | Post-Surgery (~8 wks) MRD | Follow-up (3-6mos) Monitoring Therapeutic Decision-Making Essential to differentiate between MRD testing & Monitoring Goal of the MRD Assay % ctDNA Variant Allele Frequency (VAF) Pre-Tx | Definitive Tx ctDNA Positive: • MRD present • Poor prognosis • Adjuvant tx? • Escalate tx? ctDNA Negative: • MRD absent • Good prognosis • De-escalate tx? • Omit adjuvant tx? adapted from Ulrich et al. Cancers 2021 [footer, left edge cut off] ...dapted from David Gandara, UC Davis; Ulrich B, et al. Cancers (Basel) 2021;13:3759 ILCS 2026 [photo of speaker inset at right] --- [Slide 4] CONCLUSIONS KEY TAKEAWAYS • Multiple ctDNA platforms; tumor-informed assays have higher sensitivity and lower false positives • ctDNA-MRD is a strong prognostic biomarker in resected NSCLC, consistently associated with a high risk of disease recurrence (~2–8 months median lead time for recurrence) • Multi-omic approaches to MRD may facilitate predictive value and clinical utility in early-stage NSCLC • Clinical utility (i.e., changing treatment decisions based on ctDNA-MRD) remains unproven in NSCLC – Prospective studies are needed! – Patient anxiety and survivorship need to be considered • Ongoing trials evaluating the clinical utility of ctDNA to guide treatment escalation or de-escalation across tumor types Abbosh C, et al. Nature 2017;545:446–51; Chaudhuri AA, et al. Cancer Discov 2017;7:1394–403; Qiu B, et al. Nat Commun 2021;12:6770; Gale D, et al. Ann Oncol 2022;33:500–10; Zhang JT, et al. Cancer Discov 2022;12:1690–701; Herbst RS, et al. Nat Med 2025;31:1958–68 ILCS 2026 [photo of speaker inset at right]

Hidehito HORINOUCHI@HHorinouchi2026-11-13 · 673 impressionsSource post on X ↗

10:10 New standards in EGFR- and ALK-positive NSCLCHidehito Horinouchi

Trials on the slidesCROWNprofile eXalt3profile FLAURAprofile FLAURA2profile HARMONiprofile HARMONi-Aprofile MARIPOSAprofile MARIPOSA-2profile OptiTROP-Lung04profile PANKU-Lung01profile SAFFRONprofile

Summarising over 20 years of evidence in such an elegant, calm, and comprehensive way takes real vision! Absolutely jaw-dropping presentation by @HHorinouchi on EGFR- and ALK-driven NSCLC at @LungSummit in. Lausanne and on-line! @IASLC @peters_solange @Alfdoc2

ILCS 2026 slide — Hidehito Horinouchi, New standards in EGFR- and ALK-positive NSCLC: ALK-POSITIVE NSCLC AS ANOTHER TEXTBOOK OF TARGETED THERAPY

Alessio Cortellini@ACortelliniMD2026-11-13 · 1,651 impressionsSource post on X ↗

Another brainstorming #ILCS26 in Lausanne hosted by @Alfdoc2 and @peters_solange with @HHorinouchi giving a state-of- the art current #EGFR and #ALK landscape in #NSCLC, including the plethora of options and issues on access, cost and QoL 👏

ILCS 2026 slide — Hidehito Horinouchi, New standards in EGFR- and ALK-positive NSCLC: EGFR-POSITIVE NSCLC AS A TEXTBOOK OF TARGETED THERAPY

[Slide 2] EGFR-POSITIVE NSCLC AS A TEXTBOOK OF TARGETED THERAPY [Matrix of colored boxes; column headers: Chemo | VEGFi | 3rd G | 2nd G | 1st G | EGFR Select | Partially Select | Non Select | 2020s | 2010s | 2000s] [Bar chart, median PFS by trial:] IDEAL-1 | 2.7 m BR.21 | 2.2 m ISEL | 3 m INTEREST | 2.2 m V-15-32 | 2 m ICOGEN | 4.6 m IPASS | 5.7 m First-SIGNAL | 5.8 m WJTOG3405 | 9.2 m NEJ002 | 10.8 m OPTIMAL | 13.1 m EURTAC | 9.7 m CONVINCE | 11.2 m LUX-Lung 3 | 11.1 m LUX-Lung 6 | 11 m LUX-Lung 7 | 11 m ARCHER 1050 | 14.7 m JO25567 | 16 m NEJ026 | 16.9 m CTONG1509 | 17.9 m BEVERLY | 15.4 m RELAY | 19.4 m FLAURA | 18.9 m AENEAS | 19.3 m FURLONG | 20.8 m LASER301 | 20.6 m NEJ009 | 20.9 m FLAURA2 | 25.5 m [Inset Kaplan–Meier curves labeled ISEL, IPASS, NEJ002; inset text illegible] [citation list, small print: Fukuoka M et al., JCO, 2003; Shepherd FA et al., NEJM, 2005; Thatcher N et al., Lancet, 2005; Kim ES et al., Lancet, 2008; Maruyama R et al., JCO, 2008; Shi Y et al., Lancet Oncol, 2013; Mok TS et al., NEJM, 2009; Han JY et al., JCO, 2012; Mitsudomi T et al., Lancet Oncol, 2010; Maemondo M et al., NEJM, 2010; Zhou C et al., Lancet Oncol, 2011; Rosell R et al., Lancet Oncol, 2012; Shi YK et al., Ann Oncol, 2017; Sequist LV et al., JCO, 2013; Wu YL et al., Lancet Oncol, 2014; Park K et al., Lancet Oncol, 2016; Wu YL et al., Lancet Oncol, 2017; Seto T et al., Lancet Oncol, 2014; Saito H et al., Lancet Oncol, 2019; Zhou Q et al., Cancer Cell, 2021; Piccirillo MC et al., JTO, 2022; Nakagawa K et al., Lancet Oncol, 2019; Soria JC et al., NEJM, 2018; Lu S et al., JCO, 2022; Shi Y et al., Lancet Respir Med, 2022; Cho BC et al., JCO, 2023; Hosomi Y et al., JCO, 2020; Planchard D et al., NEJM, 2023; Cho BC et al., NEJM, 2024; Wu YL et al., ESMO, 2025 — partly illegible] Hidehito Horinouchi, MD, PhD. @Hhorinouchi horinou@ncc.go.jp ILCS 2026 [photo of speaker inset at right] --- [Slide 3] ALK-POSITIVE NSCLC AS ANOTHER TEXTBOOK OF TARGETED THERAPY [Matrix of colored boxes; column headers: 3rd G | 2nd G | 1st G | ALK Select | 2020s | 2010s] [Bar chart, median PFS by trial:] PROFILE 1001 | 9.7 m PROFILE 1007 | 7.7 m PROFILE 1014 | 10.9 m PROFILE 1029 | 11.1 m ASCEND-4 | 16.6 m ALTA-1L | 24 m eXalt3 | 25.8 m Envonalkib | 24.87 m INSPIRE | 27.7 m AF-001JP | 40 m J-ALEX | 34.1 m ALEX | 34.8 m ALESIA | 41.6 m CROWN | >84 m [Inset Kaplan–Meier curve labeled CROWN; inset text (median follow-up for PFS in lorlatinib and crizotinib arms, numbers-at-risk table) too small to read: illegible] EGFR-POSITIVE NSCLC • EGFR-TKIs: Born WITHOUT rational biomarkers • Relatively HETEROGENEOUS tumor from beginning • Transition to COMBINATION strategies even in 1st line. ALK-POSITIVE NSCLC • ALK-TKIs: Born WITH rational biomarker • Relatively UNIFORM tumor especially in 1st line • TKI MONOTHERAPY remaining standard in 1st line [citations, small print, partly illegible: Kwak EL et al., NEJM, 2010; Shaw AT et al., NEJM, 2013; Solomon BJ et al., NEJM, 2014; Wu YL et al., JTO, 2018; Soria JC et al., Lancet, 2017; Camidge DR et al., NEJM, 2018; Horn L et al., JAMA Oncol, 2021; Yang Y et al., STTT, 2023; Seto T et al., Lancet Oncol, 2013; Hida T et al., Lancet, 2017; Peters S et al., NEJM, 2017; Zhou C et al., Lancet Respir Med, 2019; Shaw AT et al., NEJM, 2020] Hidehito Horinouchi, MD, PhD. @Hhorinouchi horinou@ncc.go.jp ILCS 2026 [photo of speaker inset at right] --- [Slide 4] STRUGGLES TO OVERCOME RESISTANCES [Matrix of colored boxes; column headers: EGFR/HER3 ADC | METi | EGFRi | TROP2 ADC | HER3 ADC | VEGFi | ICI | Chemo | 3rd G | 1st G | MET Select | EGFR Select | 2020s | 2010s] [Bar chart, median PFS by trial:] IMPRESS | 5.4 m KEYNOTE-789 | 5.6 m CheckMate 722 | 5.6 m ORIENT-31 | 7.2 m ATTLAS | 8.48 m NEJ043 | 7.4 m IMpower 151 | 8.5 m HARMONi-A | 7.1 m HARMONi | 6.8 m HERTHENA-Lung01 | 5.5 m HERTHENA-Lung02 | 5.8 m TROPION-Lung05 | 5.8 m OptiTROP-Lung04 | 8.3 m MARIPOSA-2 | 6.3 m SACHI | 8.2 m SAFFRON | 7.6 m PANKU-Lung01 | 11.1 m [Inset Kaplan–Meier curves labeled KEYNOTE 789, HARMONi, OptiTROP-Lung04; inset text illegible] ISSUES IN CLINICAL DEVELOPMENT • EMERGING but UNSATISFACTORY new strategies with mPFS around 5-10 months • COMBINATION strategies necessary, especially in TKI resistant EGFR+ NSCLC • Limited new BIOMARKERS other than classical actionable gene alterations ("MET High" first in 25 years) [citations, small print: Soria JC et al., Lancet Oncol, 2015; Yang JC et al., JCO, 2024; Mok T et al., JCO, 2024; Lu S et al., Lancet Oncol, 2022; Park S et al., JCO, 2024; Watanabe S et al., EJC, 2024; Zhou C et al., Nat Med, 2025; Fang W et al., JAMA, 2024; Le X et al., Lancet Oncol, 2026; Yu HA et al., JCO, 2023; Mok T et al., ASCO, 2025; Sands J et al., JCO, 2025; Fang W et al., NEJM, 2025; Passaro A et al., Ann Oncol, 2024; Lu S et al., Lancet, 2025; Lu S et al., NEJM, 2026; Zhang L et al., Lancet, 2026] Hidehito Horinouchi, MD, PhD. @Hhorinouchi horinou@ncc.go.jp ILCS 2026 [photo of speaker inset at right]

Giannis Mountzios@g_mountzios2026-11-13 · 808 impressionsSource post on X ↗

@ACortelliniMD @HHorinouchi @LungSummit @IASLC @peters_solange @Alfdoc2 Definitely an innovative way of getting the data on one slide, even that last “bar”!

Andy Johnson@andylain032026-11-13 · 176 impressionsSource post on X ↗

10:35 Other actionable genomic alterations, incl. HER2 and ROS1Telma Sequeira

Trials on the slidesARROS-1profile

🆙 #ILCS2026 @LungSummit 🔥Other Actionable Genomic Alterations, including HER2 and ROS1 🎙️ @TelmaSequeiraMD ▶️Registration is open: #LCSM @OncoAlert

ILCS 2026 slide — Telma Sequeira, Other actionable genomic alterations, incl. HER2 and ROS1: 7 RARE DRIVERS, VARIOUS APPROVALS OVER 10 YEARS

[Slide 1] [Room photo of projected slide; speaker video inset] 7 RARE DRIVERS, VARIOUS APPROVALS OVER 10 YEARS [Timeline 2016-2026 by driver, approval labels:] MET (exon 14 · overexpression): Capmatinib (2020); Tepotinib (2021); Teliso-V (c-MET overexpression) (2025) ROS1 (fusion): Crizotinib (2016); Entrectinib (2019); Repotrectinib (2023); Taletrectinib (2025); Zidesamtinib (post-TKI) (2026) HER2 (mutation · overexpression): T-DXd (prior therapy) (2022); T-DXd (tissue-agnostic · IHC 3+) (2024); Zongertinib (prior therapy 2025 · first line 2026); Sevabertinib (prior therapy) (2025) BRAF (V600E): Dabrafenib + trametinib (2017); Encorafenib + binimetinib (2023) RET (fusion): Pralsetinib; Selpercatinib (2020) NTRK (fusion): Larotrectinib (tissue-agnostic) (2018); Entrectinib (tissue-agnostic) (2019); Repotrectinib (tissue-agnostic) (2024) NRG1 (fusion): Zenocutuzumab (2024) 1. Chul-Kim, WCLC 2026 ILCS 2026 --- [Slide 2] [Room photo of projected slide; speaker video inset] FIRST LINE: TKI-NAÏVE COHORTS, ALL SINGLE-ARM Trial | Crizotinib PROFILE 1001 phase 1 | Entrectinib STARTRK / ALKA pooled phase 1/2 | Repotrectinib TRIDENT-1 phase 1/2 | Taletrectinib TRUST-I + II pooled phase 2 | Zidesamtinib ARROS-1 phase 1/2 n (TKI-naïve) | 53 | 168 | 121 | 157 | 94 ORR (primary) | 72% | 68% | 79% | 90% | 94% Median PFS | 19.3 mo | 15.7 mo | 30.2 mo | 46.1 mo | NR (12-mo PFS 90%) Overall survival | median 51.4 mo | median 47.8 mo | median 74.6 mo | 48-mo OS 58% | Not reported IC-ORR (n measurable) | — | 80% (25) | 89% (9) | 77% (17) | 100% (10) Median follow-up | 62.6 mo | 29.1 mo | 37 mo | 35.5 mo | 15.2 mo No cross-trial efficacy comparison intended. CAVEAT: populations differ (84% Asian in TRUST vs 31% Asia-Pacific in ARROS-1), and so do follow-up and CNS imaging schedules. Only TRIDENT-1 mandated surveillance brain MRI in all patients, so icPFS comparisons are asymmetric. Randomised trials vs crizotinib: TRIDENT-3, TRUST-III. No phase 3 planned for zidesamtinib. 1. Shaw AT, et al. Ann Oncol 2019;30:1121–6. 2. Drilon A, et al. JTO Clin Res Rep 2022;3:100332. 3. Drilon A, et al. N Engl J Med 2024;390:118–31; Cho BC, et al. WCLC 2025. 4. Bazhenova L, et al. AACR 2026, CT300. 5. Drilon AE, et al. WCLC 2026 (data cut-off 16 Apr 2026). ILCS 2026 --- [Slide 3] [Room photo of projected slide; speaker video inset] HER2: STRATIFY FIRST, THEN SEQUENCE ? ACTIVATING MUTATION | FIRST LINE | AT PROGRESSION TKD (exon 19/20, incl. YVMA): - Selective TKI zongertinib / sevabertinib [Phase 1/2] → T-DXd or chemo-IO? [No data] - T-DXd [Phase 3] → Selective TKI or chemo-IO? [Phase 1/2] - Chemo-IO EU default today [Phase 3 (control arm)] → T-DXd or selective TKI [Phase 2] non-TKD (ECD / TMD, e.g. S310F): - T-DXd or chemo-IO [Phase 1/2]; TKIs less active: zongertinib ORR 30% (n=20, pretreated) → the other one: chemo-IO after T-DXd, or T-DXd after chemo-IO 1. Heymach JV, et al. N Engl J Med 2025; 2026. 2. Le X, et al. N Engl J Med 2025. 3. Rotow J, et al. WCLC 2026. 4 Li BT, et al. N Engl J Med 2022. ILCS 2026 --- [Slide 4] [Room photo of projected slide; speaker video inset] IN BRIEF TAKE HOME MESSAGES 01 Test broadly and correctly: Rare drivers are actionable if we find them. 02 Expanding number of treatment options for each subset, we are faced with the challenge of how to pick the best 1st option 03 Improving toxicity profile of new treatments is important as patients are living longer ILCS 2026

Hidehito HORINOUCHI@HHorinouchi2026-11-13 · 1,064 impressionsSource post on X ↗

11:20 Targeting (K)RAS with new compoundsChristine Lovly

Trials on the slidesKrascendo 1profile

🆙 #ILCS2026 @LungSummit 🔥Targeting (K)RAS with New Compounds 🎙️ @christine_lovly ▶️Registration is open: #LCSM @OncoAlert

ILCS 2026 slide — Christine Lovly, Targeting (K)RAS with new compounds: MUTANT KRAS BIOLOGY

[Slide 1] MUTANT KRAS BIOLOGY KRAS MUTANT NSCLC PREVALENCE RATES VARY GLOBALLY United States ~28% Europe ~30% Middle East ~20% Latin America ~10–13% East Asia ~5–8% Southeast Asia ~14–20% Judd J, et al. Mol Cancer Ther 2021;20:2577–84; Carrot-Zhang J, et al. Cancer Discov 2021;11:591–8; AlJassim A, et al. J Immunother Precis Oncol 2025;8:233–41; Wu SG, et al. JTO Clin Res Rep 2020;2:100140; Cho BC, et al. Curr Oncol 2022;29:2154–64; Dang AH, et al. Sci Rep 2020;10:2707; Rajadurai P, et al. J Mol Pathol 2023;4:31–43 ILCS 2026 [World map with regional prevalence callouts; inset video of female speaker at podium] --- [Slide 2] NEXT-GENERATION KRAS THERAPIES ONGOING TRIALS ARE EVALUATING KRASG12C INHIBITOR MONOTHERAPY AND COMBINATION REGIMENS IN KRASG12C-MUTANT METASTATIC NSCLC KRAS G12C inhibitor | Trial | Phase | PD-L1 status | Treatment arms | Primary endpoint(s) 1L | Adagrasib | KRYSTAL-4 | 3 | All comers | Adagrasib + pembrolizumab + chemo vs PBO + pembrolizumab + chemo | PFS, OS 1L | Adagrasib | KRYSTAL-7 | 3 | TPS ≥ 50% | Adagrasib + pembrolizumab vs pembrolizumab | PFS, OS 1L | Sotorasib | CodeBreaK 202 | 3 | TPS < 1% | Sotorasib + chemo vs pembrolizumab + chemo | PFS, OS 1L | Olomorasib | SUNRAY-01 Part A | 3 | TPS ≥ 50% | Olomorasib + pembrolizumab vs PBO + pembrolizumab | PFS 1L | Olomorasib | SUNRAY-01 Part B | 3 | All comers | Olomorasib + pembrolizumab + chemo vs PBO + pembrolizumab + chemo | PFS 1L | Divarasib | Krascendo 2 | 3 | All comers | Divarasib + pembrolizumab vs pembrolizumab + chemo | PFS, OS 1L | Glecirasib | JAB-21822-3002 | 3 | All comers | Glecirasib + JAB-3312 vs tislelizumab + chemo | PFS 1L | Calderasib | KANDLELIT-004 | 3 | TPS ≥ 50% | Calderasib + pembrolizumab vs PBO + pembrolizumab | PFS 1L | Calderasib | KANDLELIT-007 | 3 | All comers | Calderasib + pembrolizumab SC vs pembrolizumab SC + chemo | PFSa 1L | Elironrasib | RASolve 307 | 3 | All comers | Elironrasib + pembrolizumab + chemo | PFS 2L+ | Divarasib | Krascendo 1 | 3 | All comers | Divarasib vs adagrasib or sotorasib | PFS 2L+ | Garsorasib | D1553-III-01 | 3 | All comers | Garsorasib vs docetaxel | PFS aIn patients with TPS ≥ 1% ClinicalTrials.gov: NCT06875310 (KRYSTAL-4); NCT04613596 (KRYSTAL-7); NCT05920356 (CodeBreaK 202); NCT06119581 (SUNRAY-01); NCT06793215 (Krascendo 2); NCT06416410 (JAB-21822-3002); NCT06345729 (KANDLELIT-004); NCT07190248 (KANDLELIT-007); NCT06497556 (Krascendo 1); NCT06300177 (D1553-III-01) ILCS 2026 [Inset video of female speaker at podium] --- [Slide 3] NEXT-GENERATION KRAS THERAPIES A VARIETY OF OTHER KRAS/RAS PATHWAY-TARGETING APPROACHES ARE BEING EXPLORED IN ADVANCED/METASTATIC NSCLC KRAS G12C: KRAS G12C(OFF) inhibitors; KRAS G12C(ON/OFF) inhibitors KRAS G12D: KRAS G12D(OFF) inhibitors; KRAS G12D(ON/OFF) inhibitors; KRAS G12D PROTACs; KRAS G12D–preferring (OFF) inhibitors Multi-RAS: Pan-RAS inhibitors; Pan-KRAS inhibitors; Pan-KRAS PROTACs RAS Signaling Pathways: c-MET ADCs; HER2 ADCs; Many others... Adapted from Riedl JM, et al. Cancer Cell 2026;44:471–97 ILCS 2026 [Inset video of female speaker] --- [Slide 4] NEXT-GENERATION KRAS THERAPIES KRAS MUTANT LUNG CANCER: SO MUCH HOPE, SO MANY QUESTIONS Most prevalent oncogenic driver in NSCLC <-> Expanding repertoire of allele-specific and pan-KRAS inhibitors of various MOAs Current knowledge gaps 1. CNS efficacy of novel agents 2. "Best" MOA for targeting: on, off, on/off, degrader, etc. 3. Need for allele specific vs. pan KRAS vs. pan RAS drugs 4. Sequencing of RAS targeting agents 5. Impact of other biomarkers (PD-L1, co-mutations) on therapeutic decision making 6. Resistance mechanisms across different generations of inhibitors and across different classes of compounds 7. Development and prioritization of combination approaches across lines of therapy 8. Best practices for toxicity mitigation 9. Strategies for ensuring access to novel agents as they are approved ILCS 2026 [Inset video of female speaker]

Hidehito HORINOUCHI@HHorinouchi2026-11-13 · 645 impressionsSource post on X ↗

#ILCS26 @christine_lovly delivering a comprehensive overview of #KRAS inhibitors in #NSCLC emphasizing on target selectivity, co-mutations, patient subgroups and combinations with chemo+/- moving to the 1L setting . Exciting times to follow

ILCS 2026 slide — Christine Lovly, Targeting (K)RAS with new compounds: NEXT-GENERATION KRAS THERAPIES

[Slide 1] [Room photo; sponsor screens read "Revolution Medicines"; banners IASLC, OncoViews, INTERNATIONAL LUNG CANCER SUMMIT] NEXT-GENERATION KRAS THERAPIES ONGOING TRIALS ARE EVALUATING KRASG12C INHIBITOR MONOTHERAPY AND COMBINATION REGIMENS IN KRASG12C-MUTANT METASTATIC NSCLC KRASG12C inhibitor | Trial | Phase | PD-L1 status | Treatment arms | Primary endpoint(s) Adagrasib | KRYSTAL-4 | 3 | All comers | Adagrasib + pembrolizumab + chemo vs PBO + pembrolizumab + chemo | PFS, OS Adagrasib | KRYSTAL-7 | 3 | TPS ≥ 50% | [illegible] | PFS, OS Sotorasib | CodeBreaK 202 | 3 | TPS < 1% | Sotorasib + chemo vs pembrolizumab + chemo | PFS, OS Olomorasib | SUNRAY-01 Part A | 3 | TPS ≥ 50% | Olomorasib + pembrolizumab vs PBO + pembrolizumab | PFS Olomorasib | SUNRAY-01 Part B | 3 | All comers | Olomorasib + pembrolizumab + chemo vs PBO + pembrolizumab + chemo | PFS Divarasib | Krascendo 2 | 3 | All comers | Divarasib + pembrolizumab vs pembrolizumab + chemo | PFS, OS Glecirasib | JAB-21822-3002 | 3 | All comers | Glecirasib + JAB-3312 vs tislelizumab + chemo | PFS Calderasib | KANDLELIT-004 | 3 | TPS ≥ 50% | Calderasib + pembrolizumab vs PBO + pembrolizumab | PFS Calderasib | KANDLELIT-007 | 3 | All comers | Calderasib + pembrolizumab SC vs pembrolizumab SC + chemo | PFS Elironrasib | RASolve 307 | 3 | All comers | Elironrasib + pembrolizumab + chemo | PFS Divarasib | Krascendo 1 | 3 | All comers | Divarasib vs adagrasib or sotorasib | PFS Garsorasib | D1553-III-01 | 3 | All comers | Garsorasib vs docetaxel | PFS [Footnote and ClinicalTrials.gov NCT list too small to read reliably] ILCS 2026 --- [Slide 2] NEXT-GENERATION KRAS THERAPIES A VARIETY OF OTHER KRAS/RAS PATHWAY-TARGETING APPROACHES ARE BEING EXPLORED IN ADVANCED/METASTATIC NSCLC KRAS G12C: KRAS G12C(OFF) inhibitors; KRAS G12C(ON/OFF) inhibitors KRAS G12D: KRAS G12D(OFF) inhibitors; KRAS G12D(ON/OFF) inhibitors; KRAS G12D PROTACs; KRAS G12D–preferring (OFF) inhibitors Multi-RAS: Pan-RAS inhibitors; Pan-KRAS inhibitors; Pan-KRAS PROTACs RAS Signaling Pathways: c-MET ADCs; HER2 ADCs; Many others... Adapted from Riedl JM, et al. Cancer Cell 2026;44:471–97 ILCS 2026 [Room photo with projected slide and inset video of speaker; color cast on image] --- [Slide 3] NEXT-GENERATION KRAS THERAPIES KRAS MUTANT LUNG CANCER: SO MUCH HOPE, SO MANY QUESTIONS Most prevalent oncogenic driver in NSCLC <-> Expanding repertoire of allele-specific and pan-KRAS inhibitors of various MOAs Current knowledge gaps [partially obscured by projector color banding] 1. CNS efficacy of novel agents 2. "Best" MOA for targeting: on, off, on/off, degrader, etc. 3. Need for allele specific vs. pan KRAS vs. pan RAS drugs 4. Sequencing of RAS targeting agents 5. Impact of other biomarkers (PD-L1, co-mutations) on therapeutic decision making 6. Resistance mechanisms across different generations of inhibitors and across different classes of compounds 7. Development and prioritization of combination approaches across lines of therapy 8. Best practices for toxicity mitigation 9. Strategies for ensuring access to novel agents as they are approved ILCS 2026 [Room photo with projected slide; heavy color banding]

Giannis Mountzios@g_mountzios2026-11-13 · 627 impressionsSource post on X ↗

11:50 The ADC wave: integrating new agents in NSCLCDavid Planchard

Trials on the slidesEVOKE-03profile OptiTROP-Lung05profile OptiTROP-Lung06profile

🆙 #ILCS2026 @LungSummit 🔥The ADC WAVE: Integrating New Agents in NSCLC 🎙️ @dplanchard ▶️Registration is open: #LCSM @OncoAlert

ILCS 2026 slide — David Planchard, The ADC wave: integrating new agents in NSCLC: ADC THERAPIES

[Slide 1] ADC THERAPIES PRECISION BIOMARKER PROFILING Antibody | Payload | Linker target-cell interactions ADC delivery TARGETED DELIVERY CHEMOTHERAPY MECHANISMS CELL CYCLE INTERRUPTION ANTI-METABOLITE ACTION DNA CROSS-LINKING CHEMOTHERAPY SYSTEMIC CIRCULATION ADCs better than Chemo in selected NSCLC populations ?! [illustrative graphic; photo of speaker inset at right] --- [Slide 2] Is 1L Chemotherapy Obsolete? The ADC + IO Era GUSTAVE ROUSSY CANCER CAMPUS GRAND PARIS Trial (NCT) | Experimental arm | Control arm | Population | Primary endpoint | Status OptiTROP-Lung05 (NCT06448312) | Sac-TMT + pembrolizumab | Pembrolizumab alone | PD-L1 TPS ≥1%, any histology | PFS (BICR) | POSITIVE OptiTROP-Lung06 (NCT06711900) | Sac-TMT + pembrolizumab | Pembrolizumab + pemetrexed + platinum | PD-L1 TPS <1%, non-squamous | PFS (BICR) | POSITIVE EVOKE-03 (NCT05609968) | Sacituzumab govitecan + pembrolizumab | Pembrolizumab alone | PD-L1 TPS ≥50% | PFS, OS | NEGATIVE TROPION-Lung08 (NCT05215340) | Dato-DXd + pembrolizumab | Pembrolizumab alone | PD-L1 TPS ≥50% | PFS and OS | Ongoing; Western OptiTROP-Lung05 TROPION-Lung10 (NCT06357533) | Dato-DXd + rilvegostomig (PD-1 × TIGIT) or rilvegostomig monotherapy | Pembrolizumab alone | PD-L1 TC ≥50%, non-squamous | PFS and OS | Ongoing MK-2870-007 TroFuse-007 (NCT06170788) | Sac-TMT + Pembrolizumab | Pembrolizumab alone | PD-L1 TC ≥50% | PFS and OS | Ongoing MK-2870-023 TroFuse-023 (NCT06422143) | Post 4 cycles Pembo+carbo+pacli/nab-pacliT: Sac-TMT + Pembrolizumab | Post 4 cycles Pembo+carbo+pacli/nab-pacliT: Pembrolizumab alone | Sq-NSCLC Maintenance | OS | Ongoing Sigvotatug vedotin (NCT06758401) | Sigvotatug vedotin + Pembrolizumab | Pembrolizumab alone | PD-L1 TC ≥50% Non AGA | PFS and OS | Ongoing [photo of speaker inset at right] --- [Slide 3] The ADC Revolution: Just the Beginning of a New Wave GUSTAVE ROUSSY CANCER CAMPUS GRAND PARIS Dual-Payload (2 cytotoxic) ADCs Example of a dual-payload ADC with two different cytotoxic payloads attached via cleavable linkers Dual-Payload ADCs Cytotoxic and immunostimulatory (non-cleavable linker) Bispecific and Biparatopic ADCs Biparatopic Radioligand Payload ADCs (RLT) A diagnostic payload for dosimetry A therapeutic payload for treatment Immunostimulatory ADCs (RLT) Immunostimulatory antibody-drug conjugates (ISACs) target tumour-specific antigens and are internalized by antigen-presenting cells (APCs) via Fcγ receptors Inside APCs, tumour antigens and PRR agonists (e.g., TLR or STING agonists) are released, stimulating pro-inflammatory cytokine production, enhancing antigen presentation, recruiting immune cells, and driving a strong tumour-specific antitumour immune response PRR (Pattern Recognition Receptor) agonists, such as TLR (7/8, 9) and STING agonists, activate innate immune responses and enhance antigen presentation. Degrader Payload ADCs (DAC) POI-PROTAC-E3 Target-binding ligand to POI – Linker – E3 ligase ligand PROTAC (Proteolysis-Targeting Chimera) Degrader Ab Conjugates (DAC-PROTAC) Mechanism of Action • Monoclonal antibody binds a tumor-associated antigen and triggers internalization. • Intracellular linker cleavage under proteolytic, acidic, or reducing conditions releases the PROTAC payload. • The PROTAC recruits an E3 ligase to the protein of interest (POI) • The POI is ubiquitylated and subsequently degraded by the cellular protein degradation machinery. [remaining diagram labels and the 'Selected bispecific ADCs in development' table are too small to read: illegible] [photo of speaker inset at right] --- [Slide 4] ADCs in NSCLC – Key Take-Home Messages GUSTAVE ROUSSY CANCER CAMPUS GRAND PARIS 1. ADCs are not a homogeneous class • Efficacy and toxicity depend on the target, linker and payload • Clinical benefit must be evaluated on a drug-by-drug basis 2. Promising results from Chinese trials: the need for global validation • Impressive phase III results from Chinese trials • International studies are needed to confirm efficacy across populations 3. EGFR and HER2: validated ADC targets? • HER2: a clinically validated ADC target in HER2-mutant NSCLC • EGFR-mutant NSCLC: promising activity of ADCs targeting TROP2 and HER3 • Optimal patient selection and treatment sequencing remain to be defined 4. Moving ADCs into first-line treatment • ADC monotherapy and ADC–immunotherapy combinations are emerging as promising first-line strategies in NSCLC without AGAs • Ongoing trials will define their place alongside current first-line standards The long-awaited ADC wave is finally coming to NSCLC, but translating clinical advances into patient access will remain a major challenge in Europe. [wave illustration; photo of speaker inset at right]

Hidehito HORINOUCHI@HHorinouchi2026-11-13 · 684 impressionsSource post on X ↗

Track oncology’s top KOLs in your specialty

Create a free account, pick the tumor types you cover, and go beyond the tweet — the intelligence pharma teams use to map influence and prepare for engagement:

✓Enhanced KOL profiles

✓Pharma influence & potential advisory-board patterns

✓2025 Open Payments financial analysis

✓Social-media sentiment & trend signals

Afternoon Programme

Chairs · Solange Peters & Alfredo Addeo

14:15–17:00 CET4 of 6 with posts

14:15 Latest options in early-stage NSCLC: novel IO approaches for improved outcomesSandip Patel

Trials on the slidesAEGEANprofile CheckMate 77Tprofile KEYNOTE 671profile MDT Bridgeprofile NEOTORCHprofile

🆙 #ILCS2026 @LungSummit 🔥Latest Options in Early Stage NSCLC: Novel IO Approaches for Improved Outcomes 🎙️ @PatelOncology ▶️Registration is open: #LCSM @OncoAlert

ILCS 2026 slide — Sandip Patel, Latest options in early-stage NSCLC: novel IO approaches for improved outcomes: EARLY-STAGE NSCLC

[Slide 1] EARLY-STAGE NSCLC LOCALIZED NSCLC IMMUNOTHERAPEUTIC LANDSCAPE Neoadjuvant-only strategy CheckMate 816: Nivolumab | Neo CT IO x 3 Perioperative strategy CheckMate 77T: Nivolumab | x 4 KEYNOTE 671: Pembrolizumab | x 4 AEGEAN: Durvalumab | x 4 NEOTORCH: Toripalimab | x 3 RATIONALE 315: Tislelizumab | x 3 ± 1 SHR-1316: Adebrelimab | x 3 SURGERY Adjuvant-only strategy IMpower010: Atezolizumab KEYNOTE 091: Pembrolizumab BR31: Durvalumab Adjuvant IO (perioperative strategies) Adjuvant IO Agent | Duration | Regulatory approvals (PD-L1 population) Nivolumab | 12 mo | US: All | EU: ≥1% Pembrolizumab | 9 mo | US: All | EU: All Durvalumab | 12 mo | US: All | EU: All Toripalimab | + CT x 1 → 9 mo | [none shown] Tislelizumab | 11 mo | EU: All Adebrelimab | ~12 mo | [none shown] Adjuvant IO (adjuvant-only strategies) Adjuvant IO Agent | Duration | Regulatory approvals (PD-L1 population) Atezolizumab | CT → 12 mo IO | US: II-IIIA ≥1% | EU: 50% Pembrolizumab | (CT) → 12 mo IO | US: All | EU: All (post-CT) Durvalumab | (CT) → 12 mo IO | [none shown] [Left edge of reference list cut off:] ...PM, et al. N Engl J Med 2022;386:1973–85; Forde PM, et al. N Engl J Med 2025;393:741–52; Cascone T, et al. N Engl J Med 2024;390:1756–69; Provencio M, et al. Nat Cancer ...169–81; Wakelee H, et al. N Engl J Med 2023;389:491–503; Spicer JD, et al. Lancet 2024;404:1240–52; Heymach JV, et al. N Engl J Med 2023;389:1672–84; Yue D, et al. ...Respir Med 2025;13:119–29; Wang C, et al. Ann Oncol 2026;37:544–54; Lu S, et al. JAMA 2024;331:201–11; Wu YL, et al. AACR 2026, abstract CT014; Felip E, et al. J Clin ...025;43:2343–9; O'Brien M, et al. Lancet Oncol 2022;23:1274–86; Besse B, et al. ESMO IO 2023, abstract 120MO; Goss GD, et al. J Clin Oncol 2026;44:553–64 ...from Schlee Villodre E, Cascone lab (after Remon J); Cascone T, AACR 2026 ILCS 2026 [Inset video of male speaker at podium] --- [Slide 2] SOME AREAS OF CONTROVERSY S1801 MELANOMA Perioperative vs adjuvant only pembrolizumab [Kaplan–Meier curve] Y-axis: Probability of Event-free Survival; X-axis: Months since Randomization Legend: Neoadjuvant–adjuvant group; Adjuvant-only group P=0.004 by log-rank test No. at Risk (months 0, 6, 12, 18, 24, 30, 36 as shown) Neoadjuvant–adjuvant group | 154 | 96 | 69 | 46 | 25 | 17 | 1 Adjuvant-only group | 159 | 98 | 67 | 40 | 22 | 10 | 2 ...from Patel SP, et al. N Engl J Med 2023;388:813–23 ILCS 2026 --- [Slide 3] SOME AREAS OF CONTROVERSY LANDMARK EFS BY pCR STATUS Analysis population [Two Kaplan–Meier panels: pCRc (left) and No pCR (right); Y-axis EFS (%); X-axis Months from surgery] pCRc: Perioperative NIVOd (n = 50); Neoadj NIVO + chemo (n = 43); HR (95% CI) 0.58 (0.14–2.40) No pCR: Perioperative NIVOd (n = 73); Neoadj NIVO + chemo (n = 96); HR (95% CI) 0.65 (0.40–1.06) No. at risk (pCR panel; months 0, 6, 12, 18, 24, 30, 36, 39 approx.) Perioperative NIVO | 50 | 50 | 48 | 47 | 36 | 18 | 4 | 0 Neoadj N+C | 43 | 40 | 39 | 35 | 19 | 6 | 2 | 0 No. at risk (No pCR panel; months 0, 6, 12, 18, 24, 30, 36, 42, 48) Perioperative NIVO | 73 | 62 | 55 | 53 | 35 | 22 | 8 | 4 | 0 Neoadj N+C | 96 | 75 | 60 | 47 | 19 | 7 | 1 | 0 | 0 Median follow-up: CheckMate 816, 29.5 months; CheckMate 77T, 33.3 months. aPatients with non-evaluable pCR status were excluded. bUnweighted analyses. cpCR rates in this analysis population: perioperative NIVO, 40.7%; neoadjuvant NIVO + chemo, 30.5%. dIncludes only patients who received ≥ 1 dose of adjuvant NIVO. Adapted from Forde PM, et al. WCLC 2024, abstract PL02.08 ILCS 2026 --- [Slide 4] SOME AREAS OF CONTROVERSY ADOPT-Lung ETOP AND INSIGHT SWOG TRIALS ADOPT-Lung trial, NCT06284317 Trial design Design: International, multicentre, open-label randomized phase III trial. Sample size: 364 randomised patients (approx. 520 enrolled) Trial chair: Solange Peters Trial co-chair: Sabine Schmid Sponsor: ETOP IBCSG Partners Foundation Financial partner: AstraZeneca [ADOPT-Lung schematic too small to read] INSIGHT Trial, NCT06498635 Stage II-IIIb (v.8/9) NSCLC; 3-4 Cycles of Histology Specific Chemotherapy + Anti-PD-1/L1 → Definitive resection → pCR (Local Pathology) → Randomize 1:1 → Durvalumab x 12 months / Surveillance Endpoints: Primary: DFS; Secondary: OS, toxicity, EFS Inclusion: ECOG 0/1; R0 resection; No known EGFR/ALK; Confirmed PD-L1 status Stratification factors: N0/N1 v N2N3; PD-L1 (<1% v ≥1%); Histology (Sq v NSq) Exploratory Objectives: AI based assessment; ctDNA QOL Objectives: Primary: FACT-L TOI @ 6 months; Secondary: FACT-BRM Pts can enroll on optional pre-screening study ClinicalTrials.gov NCT06284317; ClinicalTrials.gov NCT06498635 ILCS 2026

Hidehito HORINOUCHI@HHorinouchi2026-11-13 · 611 impressionsSource post on X ↗

Dr. @PatelOncology provides an updated overview of immunotherapy in early stage NSCLC; compares and contrasts to melanoma. Neoadjuvant and perioperative have been more consistent than adjuvant but many questions remain including approach to borderline resectable cases. #ILCS26

[Slide 1] EARLY-STAGE NSCLC LOCALIZED NSCLC IMMUNOTHERAPEUTIC LANDSCAPE Neoadjuvant-only strategy CheckMate 816: Nivolumab Perioperative strategy CheckMate 77T: Nivolumab | x 4 KEYNOTE 671: Pembrolizumab | x 4 AEGEAN: Durvalumab | x 4 NEOTORCH: Toripalimab | x 3 RATIONALE 315: Tislelizumab | x 3 ± 1 SHR-1316: Adebrelimab | x 3 Adjuvant-only strategy IMpower010: Atezolizumab KEYNOTE 091: Pembrolizumab BR31: Durvalumab Neo CT IO: x 3 (CheckMate 816) SURGERY Adjuvant IO Adjuvant IO Agent | Duration | Regulatory approvals (PD-L1 population) Nivolumab | 12 mo | US: All; EU: ≥1% Pembrolizumab | 9 mo | US: All; EU: All Durvalumab | 12 mo | US: All; EU: All Toripalimab | + CT x 1 → 9 mo | [none shown] Tislelizumab | 11 mo | EU: All Adebrelimab | ~12 mo | [none shown] Adjuvant IO Agent | Duration | Regulatory approvals (PD-L1 population) Atezolizumab | CT → 12 mo IO | US: II-IIIA ≥1%; EU: 50% Pembrolizumab | (CT) → 12 mo IO | US: All; EU: All (post-CT) Durvalumab | (CT) → 12 mo IO | [none shown] Forde PM, et al. N Engl J Med 2022;386:1973–85; Forde PM, et al. N Engl J Med 2025;393:741–52; Cascone T, et al. N Engl J Med 2024;390:1756–69; Provencio M, et al. Nat Cancer 2026;7:169–81; Wakelee H, et al. N Engl J Med 2023;389:491–503; Spicer JD, et al. Lancet 2024;404:1240–52; Heymach JV, et al. N Engl J Med 2023;389:1672–84; Yue D, et al. Lancet Respir Med 2025;13:119–29; Wang C, et al. Ann Oncol 2026;37:544–54; Lu S, et al. JAMA 2024;331:201–11; Wu YL, et al. AACR 2026, abstract CT014; Felip E, et al. J Clin Oncol 2025;43:2343–9; O'Brien M, et al. Lancet Oncol 2022;23:1274–86; Besse B, et al. ESMO IO 2023, abstract 120MO; Goss GD, et al. J Clin Oncol 2026;44:553–64 Adapted from Schlee Villodre E, Cascone lab (after Remon J); Cascone T, AACR 2026 ILCS 2026 [Speaker video inset] --- [Slide 2] NEOADJUVANT IO ALONE WHAT HAPPENS IF WE DON'T ACHIEVE A pCR? With neoadjuvant chemoIO Figure 5. Depth of pathological regression and EFS by %RVT categories in the path-evaluable patient population: NIVO + chemo A. Depth of pathological regression (%RVT in the primary tumor) [Waterfall plot; y-axis: Change in tumor area with viable tumor cells (%); segments: 21% (>80% RVT), 18% (>30-80% RVT), 17% (>5-30% RVT), 45% (0-5% RVT)] B. EFS by %RVT categories [Kaplan–Meier curves; y-axis EFS (%); x-axis Months from randomization; labelled landmark values 94%, 90%, 79%, 74%, 72%, 60%, 57%, 39%; curve labels 0-5% RVT, > 5-30% RVT, > 30-80% RVT, > 80% RVT] Median EFS, months (95% CI) 0-5% RVT | NR (31.6-NR) > 5-30% RVT | NR (13.6-NR) > 30-80% RVT | 26.6 (11.6-NR) > 80% RVT | 18.9 (13.4-27.8) No. at risk (months 0, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42) 0-5% RVT | 63 | 63 | 59 | 57 | 57 | 55 | 55 | 50 | 46 | 26 | 21 | 9 | 4 | 2 | 0 > 5-30% RVT | 24 | 23 | 21 | 19 | 19 | 15 | 15 | 14 | 10 | 5 | 4 | 2 | 1 | 0 | 0 > 30-80% RVT | 25 | 24 | 21 | 18 | 15 | 15 | 13 | 11 | 9 | 5 | 5 | 2 | 1 | 1 | 0 > 80% RVT | 29 | 28 | 26 | 22 | 19 | 14 | 11 | 7 | 4 | 2 | 1 | 0 | 0 | 0 | 0 Adapted from Provencio M, et al. ASCO 2022, abstract LBA8511 ILCS 2026 --- [Slide 3] PERIOPERATIVE IO CheckMate 77T: OVERALL SURVIVAL OS | NIVO (n = 229) | PBO (n = 232) Median OS, mo (95% CI) | NR (NR-NR) | NR (NR-NR) HR (97.63% CI)a | 0.85 (0.58-1.25) [KM curve: NIVO vs PBO; labelled landmarks NIVO 80% and 78%b; PBO 77% and 72%c at 24 and 30 months] Lung cancer-specific survivald | NIVO (n = 229) | PBO (n = 232) Median lung cancer-specific survival, mo (95% CI) | NR (NR-NR) | NR (NR-NR) HR (95% CI) | 0.60 (0.40-0.89) [KM curve: NIVO vs PBO; labelled landmarks NIVO 89% and 87%e; PBO 80% and 75%f at 24 and 30 months] x-axis: Months from randomization (0, 6, 12, 18, 24, 30, 36, 42, 48, 54, 60) No. at risk (both panels, months 0, 6, 12, 18, 24, 30, 36, 42, 48, 54, 60) NIVO | 229 | 206 | 187 | 176 | 166 | 161 | 114 | 66 | 23 | 6 | 0 PBO | 232 | 216 | 197 | 178 | 161 | 152 | 103 | 52 | 20 | 7 | 0 Median follow-up (range): 41.0 months (31.3-59.8). 67 (29%) patients in the NIVO arm and 101 (44%) patients in the PBO arm received subsequent therapy of any type; 50 (22%) and 87 (38%) patients, respectively, received subsequent systemic therapy. aHR (95% CI), 0.85 (0.61-1.18). Significant boundary for OS was not met at this interim analysis. b,c95% CI: b72-83; c66-78. dExploratory analysis; events were deaths with noted reason of "disease" per investigator assessment. e95% CI: e82-91; f69-81. Adapted from Cascone T, et al. ASCO 2025, abstract LBA8010 ILCS 2026 --- [Slide 4] CONCLUSIONS SUMMARY - Anti-PD-(L)1 in localized NSCLC has potential to enhance cure rates long term - Upfront testing for EGFR/ALK/PD-L1 key – ?other never-smoking associated drivers (ROS1/RET/others) – ?IO resistance genes (STK11/KEAP1) – ?MRD testing - Neoadjuvant/perioperative chemoimmunotherapy preferred over adjuvant if feasible and patient amenable - Perioperative chemoimmunotherapy may be more efficacious (vs. neoadjuvant) in non-pCR, PD-L1 negative, MRD+ patients - ETOP ADOPT-Lung crucial study in addressing question - MDT Bridge approach for borderline resectable cases currently under investigation with promising early results ILCS 2026

Stephen V Liu, MD@StephenVLiu2026-11-13 · 1,608 impressionsSource post on X ↗

14:40 New compounds and combinations for non-oncogene-addicted advanced NSCLCAlessio Cortellini

🆙 #ILCS2026 @LungSummit 🔥New Compounds and Combinations for Non-Oncogene Addicted Metastatic NSCLC 🎙️ @ACortelliniMD ▶️Registration is open: #LCSM @OncoAlert

ILCS 2026 slide — Alessio Cortellini, New compounds and combinations for non-oncogene-addicted advanced NSCLC: PD-(L)1-ANCHORED BISPECIFICS

[Slide 1] PD-(L)1-ANCHORED BISPECIFICS PD-(L)1 BISPECIFICS: SMARTER WAY TO DELIVER COMBINATIONS? CONVENTIONAL COMBINATION: mAb A + mAb B; Independent binding; Independent PK, Systemic dual exposure VS. BISPECIFIC ANTIBODY Target A × Target B: Binding arm 1 (Target A); Binding arm 2 (Target B); Co-localized target engagement Co-localized / coordinated target engagement: Brings both targets together on the same cell or in the same microenvironment; Potential preferential activity where both targets coexist PD-1 / PD-L1 + anti-VEGF / anti-VEGFR (VEGF pathway) PD-1 / PD-L1 + anti-CTLA-4, anti-LAG-3, anti-TIGIT, etc. (Other checkpoint inhibitors) PD-1 / PD-L1 + IL-2, IL-12, IL-15, etc. (Cytokines) Made with chat-GPT Adapted from Farhangnia P, et al. Front Immunol 2023;14:1155778; Dovedi SJ, et al. Cancer Discov 2021;11:1100–17 ILCS 2026 [Inset video of male speaker] --- [Slide 2] PD-(L)1-ANCHORED BISPECIFICS PD-(L)1/CYTOKINE BISPECIFICS PD-1/IL-2α-bias (TAK-928/IBI363) IBI363 (PD1/IL2α-bias): αPD1 (high affinity); IL2v (very low affinity); Tumor: Strong efficacy; Periphery: Low toxicity; In tumor TIL expansion; Activated TST (PD1+CD25+); Bystander T (PD1-CD25+) IO treated patients (stronger signal in sqNSCLC) N=67, all dose levels -1/1.5mg/kg (n=27) cORR 25.9%, PFS 5.5 mo -3mg/kg (n=30) cORR 36.7%, PFS 9.3 mo [Waterfall plot, not legible] MarsLight-11 study IBI363 vs docetaxel in SqCC after ICI-chemotherapy failure [Study schema too small to read reliably; visible: Planned enrollment N = 600; Currently enrolling 2 countries (China, United States); Planned: 21 additional countries; TAK-928 IV (n = 300); Docetaxel IV (n = 300); Primary: OS and cORR as assessed by BICR per RECIST v1.1; Key Secondary: PFS as assessed by BICR per RECIST v1.1] ...SCO 2026 update, 3 mg/kg: median PFS 10.1 mo, median OS 18.2 mo. MarsLight-11 now has squamous and non-squamous parts, N ≈ 1,200 (NCT07217301) ...apted from Zhou J, et al. ASCO 2025; Zhou J, et al. ASCO 2026; Herbst RS, et al. ASCO 2026; ClinicalTrials.gov NCT07217301 ILCS 2026 --- [Slide 3] NOVEL IMMUNE MODULATORS "IMMUNE MODULATORS": RESIQUIMOD SULFATE (EIK1001) TeLuRide-005: Best Percentage Change in Target Lesions [Waterfall plot] Cohort - Dose Level: A1: NONSQUAMOUS NSCLC - 0.60 mg/m2; A2: NONSQUAMOUS NSCLC - 0.45 mg/m2; B1: SQUAMOUS NSCLC - 0.60 mg/m2; B2: SQUAMOUS NSCLC - 0.45 mg/m2 Inset table: (CR+PR) / Evaluable | ORR (95% CI) Total | 32/50 | 64% (49–77) Histology: NSQ | 20/34 | 59% (41–75) Histology: SQ | 12/16 | 75% (48–93) PD-L1 TPS*: < 1% | 6/11 | 55% (23–83) 1–49% | 13/21 | 62% (38–82) ≥ 50% | 12/17 | 71% (44–90) *: PD-L1 level missing in one participant with PR. TPS: Tumor proportion score Adverse Events (>20%) | Total N = 59 Fatigue | 36 (61.0%) Nausea | 27 (45.8%) Neutropenia | 25 (42.4%) Anemia | 24 (40.7%) Constipation | 20 (33.9%) Diarrhea | 19 (32.2%) Dizziness | 19 (30.5%) Thrombocytopenia | 18 (29.1%) Dyspnea | 15 (25.4%) Decreased appetite | 14 (23.7%) Headache | 14 (23.7%) Hypotension | 14 (23.7%) Pyrexia | 14 (23.7%) Vomiting | 13 (22.0%) Weight decreased | 13 (22.0%) Hypokalaemia | 12 (20.3%) ASCO 2026 update (n = 65 evaluable): ORR 63.1%; PD-L1 <1% 60.0%, 1–49% 59.3%, ≥50% 69.6% Adapted from Costin D, et al. ESMO 2025, abstract 1850MO; Wang B, et al. ASCO 2026, abstract 8568 ILCS 2026 --- [Slide 4] TUMOR-SPECIFIC IMMUNITY CELL THERAPIES: TUMOR-INFILTRATING LYMPHOCYTES (TIL) Conventional TILs: [schematic of adoptive cell transfer; 4-7 weeks] KEY ELIGIBILITY / INCLUSION: Age ≥ 18 years, ECOG 0 or 1; One lesion > 1 cm, primary or metastatic, amenable for TIL retrieval; Stable disease on ≥ 2 courses of first-line single-agents immunotherapy or chemoimmunotherapy, or progressive disease on or after first-line treatment; Asymptomatic CNS ≤ 1 cm before resection may be eligible Biopsy or resection for TIL retrieval Cohort A 1st: chemotherapy 3 cycles carboplatin AUC 5 + paclitaxel 175 mg/m2 i.v.; TIL 2.5–10 × 10^9 cells i.v. at weeks 0 and 3 Cohort B 2nd: chemotherapy 3 cycles carboplatin AUC 5 + paclitaxel 175 mg/m2 i.v.; TIL 2.5–10 × 10^9 cells i.v. at weeks 0 and 3; pembrolizumab once every 3 weeks 100 / 150 / 200 mg by body weight i.v. 1 crossover Flow: Screened 21 → TIL product 17 → Treated 13 (61.9%) → Cohort A 4 (1 crossover); Cohort B 9 -4 excluded: no pathological confirmation 3, clinical deterioration 1 -4 not treated: death before infusion, clinical deterioration, infection [per-reason counts too small to read reliably] [Adverse event bar chart: Chemotherapy-related (n=28) vs ICI-related (n=3); toxicity grade 1–4; rows include Anemia, Thrombocytopenia, Nausea, Neuropathy, Bronchial infection, Constipation, Dermatitis, Fatigue, Folliculitis, Hepatitis, Hypomagnesiemie, Lymphopenia, Myalgia, Nephritis, Neutropenic fever, Pneumoniae, Pruritis, Pulmonary embolus, UTI] Adapted from Molly Li, ESMO course 2026; Steinbusch LC, et al. ESMO 2026, abstract 2617RO ILCS 2026

Hidehito HORINOUCHI@HHorinouchi2026-11-13 · 527 impressionsSource post on X ↗

15:30 The emerging role of T-cell engagers and ADCs in SCLCNikolaj Frost

Trials on the slidesARTEMIS-008profile DeLLphi-304profile DeLLphi-305profile TAISHAN-302profile

🆙 #ILCS2026 @LungSummit 🔥The Emerging Role of T-Cell Engagers and ADCs in SCLC 🎙️ Dr. Nikolaj Frost ▶️Registration is open: #LCSM @OncoAlert

ILCS 2026 slide — Nikolaj Frost, The emerging role of T-cell engagers and ADCs in SCLC: TCEs AND ADCs IN SCLC

[Slide 1] TCEs AND ADCs IN SCLC EMERGING TARGETS FOR T-CELL ENGAGERS AND ADCs T-cell engager (TCE) | Antibody–drug conjugate (ADC) CD3 (T-cell receptor complex) DLL3 B7-H3 (et al.) T cell Tumor cell (SCLC) Perforin/ granzymes [footer, left edge cut off] ...th AI (ChatGPT) from Zhao S, et al. Nat Rev Clin Oncol 2025;22:592–616; Zippelius A, et al. Nat Rev Cancer 2025;25:925–44 ILCS 2026 [Schematic of T-cell engager and ADC mechanisms; photo of speaker inset at right] --- [Slide 2] T-CELL ENGAGERS TCE: OUTLOOK Tarlatamab DeLLphi-306: LS-SCLC DeLLphi-312: 1L upfront DeLLphi-315: s.c. Obrixtamig DAREON-Lung-1: upfront 1L Gocatamig (MK-6070) TriTAC MK-6070-002: ≥2L ± Ifinatamab-DXd MK-6070-003: 1L various combos MK-6070-004: LS-SCLC, phase 3 Alveltamig (ZG006) Trispecific 2× DLL3 ZG006-001: ≥2L, SCLC/NEC ZG006-006: ≥2L, phase 3 [footer, left edge cut off] ...linicalTrials.gov NCT06117774 (DeLLphi-306); NCT07005128 (DeLLphi-312); NCT07778316 (DeLLphi-315); NCT07472517 (DAREON-Lung-1); NCT06780137 (MK-6070-002); ...CT07227597 (MK-6070-003); NCT07908537 (MK-6070-004); NCT05978284 (ZG006-001); NCT07189455 (ZG006-006) ILCS 2026 [molecular schematics of each agent; photo of speaker inset at right] --- [Slide 3] TCEs AND ADCs INTRACRANIAL EFFICACY OF TCEs AND ADCs Brain metastases allowed (asymptomatic) Untreated BM allowed: DeLLphi-304, DeLLphi-305, IDeate-Lung01 Previously treated BM only: DeLLphi-300, DeLLphi-301, DeLLphi-303, TAISHAN-302, ARTEMIS-008* *ARTEMIS-008: protocol-defined exceptions may apply. Intracranial response / tumor shrinkage ≥30% [Bar chart, y-axis 0%, 25%, 50%, 75%; bar labels, left to right:] Tarlatamab (n=16) | DeLLphi-300 Tarlatamab (n=16) | DeLLphi-304 I-DXd (n=65) | IDeate-Lung01 Tam-Peli (n=74) | TAISHAN-302 CTx (n=13) | DeLLphi-304 CTx (n=69) | TAISHAN-302 [bar values not printed] [footnote, left edge cut off] ...efinitions differ: DeLLphi-300/-304, ≥30% shrinkage of a brain lesion ≥10 mm; IDeate-Lung01, CNS ORR (central review); TAISHAN-302, confirmed intracranial ORR. Cross-trial; ...t comparable [sources, left edge cut off] ...pted from Dowlati A, et al. J Clin Oncol 2024;42:3392–9; Mountzios G, et al. ASCO 2026, abstract 8006; Rudin CM, et al. J Clin Oncol 2026;44:261–73; ...o Y, et al. N Engl J Med 2026;395:1610–20; Zhang L, et al. WCLC 2026, abstract PL02.03 ILCS 2026 --- [Slide 4] BIOMARKERS TOWARDS BIOMARKER-GUIDED TREATMENT? SCLC (center) SCLC-A: DLL3 TCE SCLC-I: ICI SCLC-N: DLL3 TCE / SEZ6 ADC? SCLC-P: ? SCLC-I non-NE: B7-H3 ADC Adapted with AI (ChatGPT) from Boettiger K, et al. Cancer Res 2026;86:1101–12; Ross J, et al. ASCO 2026, abstract 8087; Vasseur D, et al. bioRxiv 2026 (preprint), doi:10.64898/2026.04.02.715020; Ajay A, et al. NPJ Precis Oncol 2025;9:1 ILCS 2026 [pie-style diagram of SCLC subtypes; photo of speaker inset at right]

Hidehito HORINOUCHI@HHorinouchi2026-11-13 · 932 impressionsSource post on X ↗

16:00 Debate · which is the better choice in 1L ES-SCLC? Immunotherapy + chemo / lurbinectedin vs immunotherapy + DLL3 T-cell engagersGiannis Mountzios · Anne-Marie Dingemans

Trials on the slidesDeLLphi-304profile DeLLphi-305profile IMforteprofile

🆙 #ILCS2026 @LungSummit 🔥DEBATE🗣️ ☑️Arguing for Immunotherapy + Chemo / Lurbinectedin 🎙️ @g_mountzios ☑️Arguing for Immunotherapy + DLL3 T-Cell Engagers 🎙️ @a_dingemans ▶️Registration is open: #LCSM @OncoAlert

ILCS 2026 slide — Giannis Mountzios & Anne-Marie Dingemans, Debate · which is the better choice in 1L ES-SCLC? Immunotherapy + chemo / lurbinectedin vs immunotherapy + DLL3 T-cell engagers: 1st-LINE ES-SCLC DEBATE

[Slide 1] [Room photo of projected slide; speaker video inset] 1st-LINE ES-SCLC DEBATE OPTIONS I HAVE EXPLORED PRETEND SICK ONE DAY BEFORE THE EVENT [AI-generated illustration of a man in bed with thermometer, mug reading "Flu Mode ON"] Figure generated with ChatGPT 4.0 on 29 October 2026 ILCS 2026 --- [Slide 2] [Room photo of projected slide; speaker video inset] 1st-LINE ES-SCLC DEBATE OPTIONS I HAVE EXPLORED TRY TO TEMPT ANNE-MARIE WITH A VACATION TRIP TO GREECE! [AI-generated illustration of two people at a Greek seaside table] Figure generated with ChatGPT 4.0 on 29 October 2026 ILCS 2026 --- [Slide 3] [Room photo of projected slide; speaker video inset] EFFICACY WHAT IF TCEs WERE AVAILABLE AT 2L? Induction | 1L | 2L | OS 3.2m | mPFS in IMforte: 5.4m | mOS in DeLLphi-304 from start of 2L: 13.6m | OS 22.2 m 3.2m | mOS in DeLLphi-305: 21.1 m | OS 24.3 m BUT: High Attrition rate from 1L to 2L: 40–50%!!!! Giannis Mountzios, personal opinion Paz-Ares L, et al. ASCO 2025, abstract 8006; Paz-Ares L, et al. Lancet 2025;405:2129–43; Mountzios G, et al. N Engl J Med 2025;393:349–61; Sands J, et al. ESMO 2026, abstract LBA3; Péroil M, et al. N Engl J Med 2026, doi:10.1056/NEJMoa2609482 [partly legible] ILCS 2026 --- [Slide 4] [Room photo of projected slide; speaker video inset] ACCESS IS THERE REGULAR ACCESS TO TARLATAMAB? Approved by FDA in May 2024 and the EU on 29 May 2026. 5 months after: [Colour-coded map of Europe] Spain (Dr Noemí Reguart): EU licence, no reimbursement yet X Portugal (Dr António Araújo): No reimbursement yet; available through compassionate use program that will finish soon – UK (Dr Dionysis Papadatos-Pastos): Licensed (MHRA), not recommended by NICE for the NHS; available in private sector through private insurance or out-of-pocket – Belgium (Dr Mariana Brandão): Not reimbursed yet, available through INAMI rapid access until July 2027 – Netherlands (Dr Lizza Hendriks): Not available at all-only through clinical trials X France (Dr Jordi Remon) Early access (HAS, June 2026) for 2L only – Germany (Dr Nikolaj Frost): Fully reimbursed for 2L treatment V Sweden (Dr Andreas Koulouris): EU licence, no reimbursement X Italy (Dr Jessica Menis): EU licence (class C(nn)), not reimbursed, no compassionate use X Switzerland (Dr Alfredo Addeo): Approved but not formally reimbursed, can be obtained through a special procedure Giannis Mountzios, personal opinion ILCS 2026

Hidehito HORINOUCHI@HHorinouchi2026-11-13 · 1,019 impressionsSource post on X ↗

Another exceptional brainstorming #ILCS26 hosting an amazing global faculty has come to an end: Thank you @Alfdoc2 @peters_solange @MehrpouyaMobin for the opportunity to participate on a “hot” debate in #SCLC with my dear friend @a_dingemans but mostly for your kindness and wonderful hospitality that made us feel like home…à la prochaine ! @LungSummit @CHUVLausanne @HHorinouchi @dplanchard @TelmaSequeiraMD @ACortelliniMD @PatelOncology @christine_lovly @Timothee_MD @NikolajFrost @DasMillie11

[Slide 2] INTERNATIONAL LUNG CANCER SUMMIT 2026 WHICH IS THE BEST TREATMENT IN 1st-LINE ES-SCLC? ARGUING FOR: Immunotherapy + Chemotherapy/lurbinectedin Giannis Mountzios, MD, PhD Fourth Oncology Department and Clinical Trials Unit, Henry Dunant Hospital Center, Athens, Greece @g_mountzios 13 NOVEMBER 2026 [Photo of conference room; slide shown on projection screen beside live video of speaker]

Giannis Mountzios@g_mountzios2026-11-14 · 430 impressionsSource post on X ↗

16:35 Panel · open questions & patient casesAll speakers & attendees

17:00 Closing remarksSolange Peters · Alfredo Addeo

Meeting Coverage

Posts that document the summit without mapping to a single talk: the organizer's run-up posts, faculty arriving, room photos and wrap-ups. They are kept here rather than pinned to a talk they do not belong to.

@LungSummit2026-11-09

Sponsors have no control over, or input into, the scientific content of the International Lung Cancer Summit (ILCS) 2026, and we thank them for the support that makes the day possible. We meet in Lausanne and online this Friday, 13 November. Thank you to every sponsor, and to everyone who has registered so far. ILCS 2026 faculty: @peters_solange @Alfdoc2 @DasMillie11 @HHorinouchi @TelmaSequeiraMD @christine_lovly @dplanchard @PatelOncology @ACortelliniMD @g_mountzios @a_dingemans Registration is open: #ILCS2026 #LungCancer #NSCLC #SCLC

ILCS 2026 slide — International Lung Cancer Summit, meeting coverage

International Lung Cancer Summit@LungSummit2026-11-09 · 335 impressionsSource post on X ↗

@LungSummit2026-11-10

Three days to go: NSCLC and SCLC in one day, from ctDNA to TCEs. Solange Peters (@peters_solange), of CHUV, chairs the International Lung Cancer Summit (ILCS) 2026 with Alfredo Addeo (@Alfdoc2), this Friday, 13 November, in Lausanne and online, from 09:45 CET. Registration is open: #ILCS2026 #LungCancer #NSCLC #SCLC

ILCS 2026 slide — International Lung Cancer Summit, meeting coverage: INTERNATIONAL LUNG CANCER SUMMIT 2026

[Slide 1] INTERNATIONAL LUNG CANCER SUMMIT 2026 NOV 13 FRIDAY 09:45 - 17:00 "Lung cancer care is changing on several fronts at once, with ctDNA, new targeted agents, ADCs and TCEs." SOLANGE PETERS, SWITZERLAND [Quote card with portrait photo]

International Lung Cancer Summit@LungSummit2026-11-10 · 351 impressionsSource post on X ↗

@LungSummit2026-11-10

The International Lung Cancer Summit (ILCS) 2026 runs this Friday, 13 November, from 09:45 to 17:00 CET at CHUV in Lausanne and live online. If a colleague is still deciding, please pass the flyer on. We look forward to welcoming you and your colleagues. ILCS 2026 faculty: @peters_solange @Alfdoc2 @DasMillie11 @HHorinouchi @TelmaSequeiraMD @christine_lovly @dplanchard @PatelOncology @ACortelliniMD @g_mountzios @a_dingemans Registration is open: #ILCS2026 #LungCancer #NSCLC #SCLC

ILCS 2026 slide — International Lung Cancer Summit, meeting coverage: SCIENTIFIC PROGRAM

[Slide 2] SCIENTIFIC PROGRAM TENTATIVE AGENDA 2026 9:45 | WELCOME & INTRODUCTION | S. PETERS & A. ADDEO | SWITZERLAND 9:50 | ctDNA-GUIDED DECISIONS IN LUNG CANCER: READY OR NOT? | MILLIE DAS | USA 10:10 | NEW STANDARDS IN EGFR- AND ALK-POSITIVE NSCLC | HIDEHITO HORINOUCHI | JAPAN 10:35 | OTHER ACTIONABLE GENOMIC ALTERATIONS, INCL. HER2 AND ROS1 | TELMA SEQUEIRA | PORTUGAL 11:00 | BREAK 11:20 | TARGETING (K)RAS WITH NEW COMPOUNDS | CHRISTINE LOVLY | USA 11:50 | THE ADC WAVE: INTEGRATING NEW AGENTS IN NSCLC | DAVID PLANCHARD | FRANCE 12:30 | INDUSTRY SATELLITE SYMPOSIA 14:15 | LATEST OPTIONS IN EARLY STAGE NSCLC: NOVEL IO APPROACHES FOR IMPROVED OUTCOMES | SANDIP PATEL | USA 14:40 | NEW COMPOUNDS AND COMBINATIONS FOR NON-ONCOGENE ADDICTED METASTATIC NSCLC | ALESSIO CORTELLINI | ITALY 15:10 | BREAK 15:30 | THE EMERGING ROLE OF T-CELL ENGAGERS AND ADCs IN SCLC | NIKOLAJ FROST | GERMANY 16:00 | DEBATE: WHICH IS THE BETTER CHOICE IN 1L ES-SCLC; ARGUING FOR IMMUNOTHERAPY + CHEMO / LURBINECTEDIN; ARGUING FOR IMMUNOTHERAPY + DLL3 T-CELL ENGAGERS | GIANNIS MOUNTZIOS, ANNE-MARIE DINGEMANS | GREECE, NETHERLANDS 16:35 | PANEL DISCUSSION: OPEN QUESTIONS & PATIENT CASES BY AUDIENCE | ALL SPEAKERS & ATTENDEES 17:00 | CLOSING REMARKS | S. PETERS & A. ADDEO | SWITZERLAND CME CERTIFIED UEMS·EACCME·ECMEC SGMO·SSOM·SSMO THIS CONFERENCE IS NATIONALLY AND INTERNATIONALLY ACCREDITED AND ENDORSED BY SSMO SSOM SGMO | European Accreditation Council for Continuing Medical Education (EACCME) An Institution of the UEMS | IASLC International Association for the Study of Lung Cancer | ETOP·IBCSG Foundation for International Lung & Breast Cancer Research --- [Slide 3] FACULTY INVITED SPEAKERS DAVID PLANCHARD | FRANCE NIKOLAJ FROST | GERMANY MILLIE DAS | USA HIDEHITO HORINOUCHI | JAPAN CHRISTINE LOVLY | USA ALESSIO CORTELLINI | ITALY TELMA SEQUEIRA | PORTUGAL GIANNIS MOUNTZIOS | GREECE ANNE-MARIE DINGEMANS | NETHERLANDS SANDIP PATEL | USA [Headshot photos of the ten speakers] --- [Slide 4] LOCATION IN PERSON & ONLINE REGISTRATION NOW OPEN AT LUNGSUMMIT.ORG AUDITOIRE YVES PATERNOT AGORA BUILDING | CHUV RUE DU BUGNON 25A 1005 LAUSANNE [Map: Main Entry, AGORA, CHUV Métro, Centre Hospitalier Universitaire Vaudois, University Hospital of Lausanne, Parking des Hôpitaux; QR code] SPONSORS KINDLY SUPPORTED BY AstraZeneca, AMGEN, PharmaMar, MSD, GSK, Johnson&Johnson, Eisai, Boehringer Ingelheim, Roche, Daiichi-Sankyo, REGENERON, BIONTECH, MERCK, Bristol Myers Squibb, Lilly, BeOne, Pfizer, Revolution Medicines, Takeda, GILEAD, abbvie ILCS 2026 IS MADE POSSIBLE THROUGH THE SUPPORT OF THE SPONSORS SHOWN ABOVE. FINANCIAL SUPPORT DOES NOT CONSTITUTE OR IMPLY ENDORSEMENT BY ILCS OF ANY COMPANY, PRODUCT, OR SERVICE. SPONSORS HAVE NO CONTROL OVER, OR INPUT INTO, THE INDEPENDENT SCIENTIFIC CONTENT.

International Lung Cancer Summit@LungSummit2026-11-10 · 6,751 impressionsSource post on X ↗

@HHorinouchi2026-11-10

🔥Join Us! #ILCS2026 @LungSummit 🗓️This Friday, 13 November, from 09:45 to 17:00 CET 🌍CHUV in Lausanne and Live Online 🌏Evening Timing in Asian Time Zones 🆙Updated A to Z of Lung Cancer in a Single Day 🗣️Highly Engaged, Fantastic Faculty 👥Twice as Much Time Allocated to Discussion 📺Flexible Access: Onsite, Live Streaming, and On-demand 💰Free 🆓Registration for HCPs or Scientists ▶️Registration is open: #LCSM @OncoAlert

ILCS 2026 slide — Hidehito HORINOUCHI, meeting coverage: FACULTY

Hidehito HORINOUCHI@HHorinouchi2026-11-10 · 2,227 impressionsSource post on X ↗

@LungSummit2026-11-11

The International Lung Cancer Summit (ILCS) 2026 closes with a panel on patient cases sent in by the audience. Alfredo Addeo (@Alfdoc2), of Geneva University Hospitals, chairs with Solange Peters (@peters_solange). Send a case at and join us on Friday in Lausanne or online. Registration is open: #ILCS2026 #LungCancer #NSCLC #SCLC

[Slide 1] INTERNATIONAL LUNG CANCER SUMMIT 2026 NOV 13 FRIDAY 09:45 - 17:00 "New data arrive quickly, and the hard part is deciding what they mean for the patient in front of us." ALFREDO ADDEO, SWITZERLAND [Quote card with portrait photo]

International Lung Cancer Summit@LungSummit2026-11-11 · 310 impressionsSource post on X ↗

@LungSummit2026-11-11

Can't get to Lausanne on Friday? A free Lung Summit account lets you follow every session of the International Lung Cancer Summit (ILCS) 2026 live online, from 09:45 CET on 13 November. If you have not registered yet, sign up today so your account is ready on Friday. We look forward to having you with us 🙂 ILCS 2026 faculty: @peters_solange @Alfdoc2 @DasMillie11 @HHorinouchi @TelmaSequeiraMD @christine_lovly @dplanchard @PatelOncology @ACortelliniMD @g_mountzios @a_dingemans Registration is open: #ILCS2026 #LungCancer #NSCLC #SCLC

International Lung Cancer Summit@LungSummit2026-11-11 · 325 impressionsSource post on X ↗

@LungSummit2026-11-12

The International Lung Cancer Summit (ILCS) 2026 starts tomorrow, 13 November, at 09:45 CET, with ctDNA first and the debate on first-line ES-SCLC at 16:00, at CHUV in Lausanne and online. If you have not registered yet, there is still time today. See you tomorrow 🙂 ILCS 2026 faculty: @peters_solange @Alfdoc2 @DasMillie11 @HHorinouchi @TelmaSequeiraMD @christine_lovly @dplanchard @PatelOncology @ACortelliniMD @g_mountzios @a_dingemans Registration is open: #ILCS2026 #LungCancer #NSCLC #SCLC

International Lung Cancer Summit@LungSummit2026-11-12 · 354 impressionsSource post on X ↗

@LungSummit2026-11-12

These are tomorrow's talk times at the International Lung Cancer Summit (ILCS) 2026, in Lausanne and online on 13 November, for anyone fitting the day around clinic. Safe travels to everyone coming to Lausanne tomorrow. ILCS 2026 faculty: @peters_solange @Alfdoc2 @DasMillie11 @HHorinouchi @TelmaSequeiraMD @christine_lovly @dplanchard @PatelOncology @ACortelliniMD @g_mountzios @a_dingemans Registration is open: #ILCS2026 #LungCancer #NSCLC #SCLC

International Lung Cancer Summit@LungSummit2026-11-12 · 477 impressionsSource post on X ↗

@LungSummit2026-11-13

We start at 09:45 CET in the Agora building at CHUV and live online on the International Lung Cancer Summit (ILCS) 2026 is today, 13 November, in Lausanne. We are very much looking forward to the day with you 🙂 ILCS 2026 faculty: @peters_solange @Alfdoc2 @DasMillie11 @HHorinouchi @TelmaSequeiraMD @christine_lovly @dplanchard @PatelOncology @ACortelliniMD @g_mountzios @a_dingemans Registration is open: #ILCS2026 #LungCancer #NSCLC #SCLC

International Lung Cancer Summit@LungSummit2026-11-13 · 377 impressionsSource post on X ↗

@HHorinouchi2026-11-13

🔥Join us! #ILCS2026 @LungSummit 🔜Starting in 2⃣ hours 🗓️Friday, 13 November, from 09:45 to 17:00 CET 🌍CHUV in Lausanne and Live Online 🗣️Highly Engaged, Fantastic Faculty 💰Free 🆓Registration for HCPs or Scientists ▶️Registration is open: #LCSM @OncoAlert

ILCS 2026 slide — Hidehito HORINOUCHI, meeting coverage

Hidehito HORINOUCHI@HHorinouchi2026-11-13 · 998 impressionsSource post on X ↗

@dplanchard2026-11-13

Starting the day in a great mood with wonderful presentations on thoracic oncology « Lung Cancer Summit « in Lausanne/Geneva🇨🇭 ... shaping up to be a great day! @LungSummit #lungcancer #egfr

ILCS 2026 slide — d.planchard, meeting coverage

d.planchard@dplanchard2026-11-13 · 714 impressionsSource post on X ↗

@HHorinouchi2026-11-13

🔥TROP2 normalized membrane ratio (NMR) predicts Dato-DXd outcomes in NSCLC 🆙 @NatureMedicine ☑AI-based TROP2 QCS in TROPION-PanTumor01 & TROPION-Lung01 (nonsquamous, no actionable alterations; n=221) 🎯Dato-DXd mPFS 7.2 vs 4.0 mo (HR 0.40) in NMR+ vs NMR− (interaction p=0.0098) 🎯No difference with docetaxel 🎙 @marinagarassino #LCSM @OncoAlert @Larvol @IASLC

Hidehito HORINOUCHI@HHorinouchi2026-11-13 · 813 impressionsSource post on X ↗

@dplanchard2026-11-13

Incredible day of discussions on thoracic oncology, an amazing panel of experts on stage and in the audience. Thanks for the organization and the invitation! Available to watch remotely...@LungSummit #lungcancer @peters_solange @Alfdoc2

d.planchard@dplanchard2026-11-13 · 488 impressionsSource post on X ↗

@CiolyRiveroC2026-11-13

#ILCS 2026 International Lung Cancer Summit in Lausanne! An outstanding scientific level, inspiring discussions, and a powerful reminder that multidisciplinary collaboration is not just an added value, but a cornerstone of better patient care. 💡A deeper understanding of tumour histological and molecular complexity, actionable therapeutic targets, mechanisms of secondary resistance, and the growing importance of precision medicine is a must! #lungcancer #ThoracicOncology #pathology #cytology

ILCS 2026 slide — Cioly Rivero C., meeting coverage: FRIDAY 13 NOVEMBER 2026

[Slide 2] FRIDAY 13 NOVEMBER 2026 MORNING PROGRAMME 09:45 | Welcome & introduction | SOLANGE PETERS & ALFREDO ADDEO 09:50 | ctDNA-guided decisions in lung cancer: ready or not? | MILLIE DAS 10:10 | New standards in EGFR- and ALK-positive NSCLC | [speaker name small, partly illegible] 10:35 | Other actionable genomic alterations, incl. HER2 and ROS1 | TELMA SEQUEIRA 11:00 | Open discussion & coffee break 11:20 | Targeting (K)RAS with new compounds | CHRISTINE LOVLY 11:50 | The ADC wave: integrating new agents in NSCLC | DAVID PLANCHARD 12:30 | Industry symposia [Room photo; sponsor screen shows Bristol Myers S[quibb] logo; speaker names are small and partly hard to read]

Cioly Rivero C.@CiolyRiveroC2026-11-13 · 123 impressionsSource post on X ↗